Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation- An Observational, Multi-Center Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CITRIN
- Sponsors AbbVie
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.
- 23 Feb 2017 New trial record